A federal judge tossed lawsuits regarding the federal government's requirement of drugmakers to negotiate with Medicare on drug prices.

A federal judge in New Jersey on Monday rejected Johnson & Johnson's and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the ...

Amgen's Stelara biosimilar may present J&J with an opportunity to elude Medicare price negotiations outlined in the Inflation Reduction Act.

Johnson & Johnson sued the U.S. government on Tuesday, becoming the latest drugmaker seeking to block enforcement of a program that gives Medicare the power to negotiate drug prices.

J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations Apr. 30, 2024 9:49 AM ETJohnson & Johnson (JNJ) Stock, BMY StockPFE, AZNBy: Dulan Lokuwithana, SA News Editor21 Comments ...